Regeneron Pharmaceuticals (REGN)
EBITDA Growth
0.31%
Quarterly · Period ending:
REGN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported0.31%period ending
Latest reported0.31%period ending
REGN Quarterly EBITDA YoY % (66.67% → 0.31%)
Year-over-year change
High-resolution chart · PNG
REGN ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 0.3077% | |
| -7.044% | |
| 9.6712% | |
| 17.8569% | |
| -6.0218% | |
| 25.2377% | |
| -14.3795% | |
| 31.9692% | |
| 46.369% | |
| -14.8232% | |
| -11.323% | |
| -23.7189% | |
| 14.6759% | |
| -15.1001% | |
| -44.3596% | |
| -15.0368% | |
| -72.6259% | |
| -13.9326% | |
| 99.216% | |
| 75.662% | |
| 288.728% | |
| 82.6765% | |
| 36.8427% | |
| 30.7164% | |
| 246.6994% | |
| 20.8333% | |
| 30.9087% | |
| 22.1575% | |
| -59.1177% | |
| -3.7242% | |
| 22.0052% | |
| 11.3682% | |
| 22.9983% | |
| 31.4477% | |
| 60.7089% | |
| 54.7197% | |
| 78.8614% | |
| 35.6586% | |
| 45.842% | |
| -4.6367% | |
| -12.0781% | |
| 17.593% | |
| 10.4611% | |
| 109.9876% | |
| 52.9836% | |
| 51.7099% | |
| 2.9427% | |
| -20.5493% | |
| 39.5019% | |
| 21.2113% | |
| 43.3371% | |
| 16.6792% | |
| 73.271% | |
| 421.7056% | |
| 524.8766% | |
| 529.0017% | |
| 289.4164% | |
| 194.7249% | |
| -702.7358% | |
| -84.9404% | |
| -159.7969% | |
| -35.9142% | |
| 86.5301% | |
| -1,263.4189% | |
| -49.1709% | |
| -32.8532% | |
| -32.2417% | |
| 113.3998% | |
| 20.4461% | |
| -40.8176% | |
| -197.0469% | |
| 52.0861% | |
| 39.8558% | |
| 57.8976% | |
| 71.3028% | |
| -45.8634% | |
| -34.8801% | |
| -72.3706% | |
| -113.4815% | |
| 19.3846% | |
| 27.4457% | |
| 27.028% | |
| 2,728.834% | |
| -333.7892% | |
| -184.7553% | |
| -202.8915% | |
| 161.5205% | |
| 68.1589% | |
| 63.0514% | |
| 191.1962% | |
| 60.6414% | |
| 26.5296% | |
| 2.8497% | |
| -12.534% | |
| -17.284% | |
| -37.8094% | |
| -66.3387% | |
| -73.2551% | |
| -238.2396% | |
| -51.9221% |